Evaluation of a Phenotypic Revertant of the A/Alaska/77-ts-1A2 Reassortant Virus in Hamsters and in Seronegative Adult Volunteers: Further Evidence That the Temperature-sensitive Phenotype is Responsible for Attenuation of Ts-1A2 Reassortant Viruses
Overview
Authors
Affiliations
In a previous study, a seronegative child to whom attenuated A/Alaska/77-ts-1A2 virus was administered (37 degrees C shutoff temperature for plaque formation) shed virus with an altered temperature-sensitive (ts) phenotype (40 degrees C shutoff temperature) (Murphy et al., Ann. N.Y. Acad. Sci. 354:172-182, 1980; Tolpin et al., Virology 112:505-517, 1981). This ts+ virus (FV1319) was evaluated for its level of replication in hamsters and for its virulence for humans. In hamsters, FV1319 ts+ virus replicated to the same level in the nasal turbinates as that of which the A/Alaska/77 wild-type virus replicated, but its replication in the lungs was reduced 40-fold. In contrast, the A/Alaska/77-ts-1A2 reassortant achieved a titer in hamster nasal turbinates that was significantly lower (P less than 0.005) than those achieved by the wild-type and the FV1319 viruses; the A/Alaska/77-ts-1A2 reassortant was not recoverable from the lungs. In seronegative adult volunteers, the pattern of replication of the FV1319 virus was similar to that of the A/Alaska/77 wild-type virus. The illness induced by the FV1319 ts+ virus was also similar to that caused by the wild-type virus. In contrast, the A/Alaska/77-ts-1A2 reassortant was satisfactorily attenuated in adult volunteers. These results suggest that attenuation of the A/Alaska/77-ts-1A2 reassortant virus in humans is a function of the ts phenotype: loss of this phenotype restored virulence. The ability of the A/Alaska/77-ts-1A2 reassortant to lose its ts phenotype and regain virulence during growth in a permissive host limits the usefulness of the ts-1A2 reassortants as vaccine viruses for humans.
Oxford J, Catchpole A, Mann A, Bell A, Noulin N, Gill D Curr Top Microbiol Immunol. 2022; 445:1-32.
PMID: 35704095 DOI: 10.1007/82_2022_253.
Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus.
Zhou B, Meliopoulos V, Wang W, Lin X, Stucker K, Halpin R J Virol. 2016; 90(19):8454-63.
PMID: 27440882 PMC: 5021423. DOI: 10.1128/JVI.00163-16.
Genetically engineered live attenuated influenza A virus vaccine candidates.
Parkin N, Chiu P, Coelingh K J Virol. 1997; 71(4):2772-8.
PMID: 9060631 PMC: 191400. DOI: 10.1128/JVI.71.4.2772-2778.1997.
Subbarao E, Park E, Lawson C, Chen A, Murphy B J Virol. 1995; 69(10):5969-77.
PMID: 7666501 PMC: 189492. DOI: 10.1128/JVI.69.10.5969-5977.1995.
Ghendon Y Bull World Health Organ. 1984; 62(3):493-9.
PMID: 6331910 PMC: 2536308.